
Oncotarget
Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.
Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/
Latest episodes

Sep 20, 2021 • 19min
Epigenetic Feedback and Stochastic Partitioning Can Drive Resistance to EMT
Exploring resistance to EMT in cancer cells, the podcast discusses epigenetic feedback and stochastic partitioning driving therapeutic resistance. Delving into cellular heterogeneity and mechanisms behind irreversible MET, the study highlights the complex dynamics of EMT in solid tumors.

Sep 16, 2021 • 6min
New Study: Nanoparticles Target Acute Myeloid Leukemia
Exploring the use of liposomal nanoparticles for targeted immunotherapy in fighting cancer, specifically Acute Myeloid Leukemia. The nanoTCE technology combines T cell activation with cancer therapy, offering a highly specific approach. Researchers are optimistic about the potential of this customizable technology in treating AML.

Sep 15, 2021 • 11min
Table of Contents: Volume 12, Issue #19
Listen to summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 19.
https://www.oncotarget.com/archive/v12/i19/
Cover Paper - “Nanoparticle T cell engagers for the treatment of acute myeloid leukemia”
https://doi.org/10.18632/oncotarget.28054
News - “Old drug, new trick: proton pump inhibitors find new purpose in cancer care”
https://doi.org/10.18632/oncotarget.28053 (PDF Download)
Research Paper - “Novel insights into the molecular mechanisms underlying risk of colorectal cancer from smoking and red/processed meat carcinogens by modeling exposure in normal colon organoids”
https://doi.org/10.18632/oncotarget.28058
Research Paper - “Altered glucuronidation deregulates androgen dependent response profiles and signifies castration resistance in prostate cancer” https://doi.org/10.18632/oncotarget.28059
Research Paper - “The antitumoral effects of chemerin are independent from leukocyte recruitment and mediated by inhibition of neoangiogenesis” https://doi.org/10.18632/oncotarget.28056
Research Paper - “Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer”
https://doi.org/10.18632/oncotarget.28068
Research Paper - “High expression of Myosin 1g in pediatric acute lymphoblastic leukemia” https://doi.org/10.18632/oncotarget.28055
Case Report - “Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition” https://doi.org/10.18632/oncotarget.28062
Research Perspective - “Towards precision oncology in angiosarcomas using next generation “omic” technologies” https://doi.org/10.18632/oncotarget.27996
Research Perspective - “Targeting AP-1 transcription factors by CRISPR in the prostate” https://doi.org/10.18632/oncotarget.27997
Research Perspective - “The role of dynamic phenotypes in cancer”
https://doi.org/10.18632/oncotarget.28006
Keywords - colon organoids, acute myeloid leukemia, prostate cancer, chemerin, KIF11 inhibition, breast cancer, acute lymphoblastic leukemia, ALK inhibitors, rare cancer, dynamic phenotype, Lung cancer, cancer, science, research, oncology
About Oncotarget
Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.
To learn more about Oncotarget, please visit https://www.oncotarget.com/ or connect with:
SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
LinkedIn - https://www.linkedin.com/company/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/oncotargetyoutube
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget
Oncotarget is published by Impact Journals, LLC. Please visit https://www.impactjournals.com/ or connect with @ImpactJrnls
Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Sep 14, 2021 • 19min
Evaluations in the TRAMP Prostate Cancer Model
Exploring the effectiveness of a specific bacteria in targeting and colonizing cancer tissues in a mouse prostate cancer model, highlighting its potential in cancer immunotherapy. Genetic stability of the bacteria and its combination with checkpoint blockade to reduce metastasis burden. Collaborative research involving experts from diverse fields contributing to the project's success.

Sep 10, 2021 • 8min
EMT Induced Stemness Promotes Tumor Growth
Exploring how epithelial to mesenchymal transitions drive cancer progression, enabling invasive traits. Hypoxia promotes neoangiogenesis, triggering EMT in cancer cells. Investigating EMT effects on tumor growth and angiogenesis, including the role of Fox C2 in triple negative breast cancer cells. Tumor-induced EMT transforms cancer cells into endothelial cells, aiding in neovascularization within tumors.

Sep 2, 2021 • 5min
Exercise Enhances Doxorubicin’s Antitumor Effects
Exploring the positive effects of exercise on chemotherapy in breast cancer mouse models. Study reveals that aerobic exercise enhances anti-tumor effects and reduces cardiotoxicity of chemotherapy in mice.

Sep 1, 2021 • 9min
Table of Contents: Volume 12, Issue #18
Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 18.
https://www.oncotarget.com/archive/v12/i18/
Priority Research Paper (Cover) - “Normal tissue and tumor microenvironment adaptations to aerobic exercise enhance doxorubicin anti-tumor efficacy and ameliorate its cardiotoxicity in retired breeder mice”
https://doi.org/10.18632/oncotarget.28057
Research Paper - “Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status”
https://doi.org/10.18632/oncotarget.28047
Research Paper - “Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal tandem duplication”
https://doi.org/10.18632/oncotarget.28042
Research Paper - “Impact factor and citation metrics in phase III cancer trials” https://doi.org/10.18632/oncotarget.28044
Research Paper - “Inhibition of the MAP2K7-JNK pathway with 5Z-7-oxozeaenol induces apoptosis in T-cell acute lymphoblastic leukemia” https://doi.org/10.18632/oncotarget.28040
Research Paper - “Correlation between PD-L1 expression and MET gene amplification in patients with advanced non–small-cell lung cancer and no other actionable oncogenic driver”
https://doi.org/10.18632/oncotarget.28045
Research Paper - “Effect of hypertension and medication use regularity on postoperative delirium after maxillofacial tumors radical surgery” https://doi.org/10.18632/oncotarget.28048
Review - “Anti-aging: senolytics or gerostatics (unconventional view)” https://doi.org/10.18632/oncotarget.28049
Case Report - “The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series” https://doi.org/10.18632/oncotarget.28046
Editorial - “Juvenile polyposis without a germline variant in SMAD4/BMPR1A: defining a clinically distinct polyposis syndrome” https://doi.org/10.18632/oncotarget.28023 (PDF Download)
Research Perspective - “Targeting cancer stem cells via integrin β4”
https://doi.org/10.18632/oncotarget.27977
Keywords - aerobic exercise, breast cancer, selinexor, Pim kinase, journal impact factor, T-ALL, non–small-cell lung cancer, oral tumor surgery, geroscience, senolytics, RNA sequencing, cancer stem cells, cancer, science, research, oncology
About Oncotarget
Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.
To learn more about Oncotarget, please visit https://www.oncotarget.com/ or connect with:
SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
LinkedIn - https://www.linkedin.com/company/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/oncotargetyoutube
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget
Oncotarget is published by Impact Journals, LLC. Please visit https://www.impactjournals.com/ or connect with @ImpactJrnls
Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Sep 1, 2021 • 16min
Epithelial-mesenchymal Transitions Create Endothelial Cells & Tumor Growth
Exploring how carcinoma cells undergo EMT and transform into endothelial cells, boosting tumor growth and vascularization. FOXC2 plays a key role in this process. The podcast discusses the impact of EMT on tumor progression, angiogenesis, and stem cell traits, with a focus on how EMT-induced cells acquire endothelial-like phenotypes. It also delves into the link between EMT, endothelial cells, and tumor growth, highlighting the process of vascular mimicry in cancer contexts.

Sep 1, 2021 • 5min
Promising Non-Small Cell Lung Cancer Prodrug
New drug candidate LP-184, derived from Jack-o-Lantern mushrooms, shows promising anti-tumor activity in NSCLC cell lines with therapy-refractory mutations. Study explores activation through reductive mechanisms and sensitivity in cell lines with mutations in KEAP1, KRAS, TP53, and STK11.

Aug 19, 2021 • 8min
C. Elegans Sniff Out Early Pancreatic Cancer
Researchers explored using C. elegans to detect early pancreatic cancer biomarkers. A study with 83 patients showed promising results for early detection. The potential of using chemotaxis in cancer screening was highlighted, emphasizing further research needed.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.